Hey guys! In this week’s industry specific news, we’ll cover some interesting developments for MindMed, Mydecine, Cybin, HAVN, and a private company called WAKE. One of the biggest highlights is that HAVN might enter in direct competition with MindMed by penetrating the cluster headaches market. Stay tuned till the end the hear more on this specific news!
Timestamps:
0:00 - Intro
1:00 - MindMed Begins a Mescaline Study
4:35 - MindMed & The Chopra Foundation
8:30 - Cybin Progresses Phase 2a psilocybin study
11:56 - Mydecine announces Q1 Financials
14:16 - Havn Life Sciences enters the Cluster Headaches Game
16:30 - Wake Receives First-Ever Approval for Psilocybin for Anxiety & Depression
Enjoy!
Links:
MindMed (MNMD/ MMED / MMQ)) Begins a Mescaline Study:
https://mindmed.co/news/press-release/mindmed-announces-the-approval-of-mescaline-study/
MindMed Partners Up with The Chopra foundation:
https://mindmed.co/news/press-release/the-chopra-foundation-and-mindmed-enter-into-letter-of-intent-to-partner-on-the-future-of-psychedelic-medicines-mental-wellbeing/
Cybin (CYBN) Progresses Phase IIa psilocybin film strip study:
https://www.clinicaltrialsarena.com/news/cybin-phase-ii-psilocybin/
Mydecine (MYCO / MYCOF) Q1 Financials:
https://psilocybinalpha.com/news/mydecine-reports-first-quarter-2021-financial-results-and-provides-business-update
Havn Life Sciences (HAVN/ HAVLF/ 5NP) Begins to Study Cluster Headaches
https://havnlife.com/havn-life-enters-into-agreement-to-acquire-clinical-stage-ip-for-development-of-lsd-derived-api-for-cluster-headaches/
Wake Receives First-Ever Approval for Psilocybin Microdose Study for Anxiety and Depression
https://psychedelicspotlight.com/wake-psilocybin-microdose-study/
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Video editing: @themyaholy
https://benzinga.grsm.io/jameshallifa...
https://benzinga.grsm.io/thepsychedel...
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #PsychedelicStocks #HAVN
Psychedelic Platform Field Trip Health Gets Uplisting Conditional Approval for Toronto Stock Exchange
BusinessPsychedelic Drug Development Company Mynd Life Sciences Goes Public on the CSE
BusinessAttorneys General, Organizations, Specialists Sue DEA for Access to Psilocybin for Terminally Ill Patients
Policy, TreatmentMindMed Facing Competition From HAVN? Plus Financials and Phase 2 Trials (MNMD, CYBIN, HAVN, MYCO)
VideosIsraelis and Palestinians Turn to Ayahuasca to Heal Conflict Wounds
CultureInterview With Dr. Gorman
PodcastsPsychedelic Business Roundup- Mike Tyson’s New Investment
Psychedelic Spotlight VideosResearch to Look at Psychedelics for Autism Treatment
ResearchFDA Approves First-Ever MDMA Study for Therapist Volunteers to Better Treat PTSD Patients
ResearchWhat Is Changa? The Psychedelic You’ve Likely Never Heard Of (Yet)
Treatment